ES2445846R1 - Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos - Google Patents

Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos Download PDF

Info

Publication number
ES2445846R1
ES2445846R1 ES201390009A ES201390009A ES2445846R1 ES 2445846 R1 ES2445846 R1 ES 2445846R1 ES 201390009 A ES201390009 A ES 201390009A ES 201390009 A ES201390009 A ES 201390009A ES 2445846 R1 ES2445846 R1 ES 2445846R1
Authority
ES
Spain
Prior art keywords
diabetes
medicament
prepare
treatment
metabolic disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES201390009A
Other languages
English (en)
Spanish (es)
Other versions
ES2445846A2 (es
Inventor
Oleg Iliich Epshtein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2445846(R1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Individual filed Critical Individual
Publication of ES2445846A2 publication Critical patent/ES2445846A2/es
Publication of ES2445846R1 publication Critical patent/ES2445846R1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES201390009A 2010-07-21 2011-07-15 Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos Pending ES2445846R1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
RU2010130348 2010-07-21
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051 2011-07-01
PCT/IB2011/002177 WO2012010966A2 (en) 2010-07-21 2011-07-15 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders

Publications (2)

Publication Number Publication Date
ES2445846A2 ES2445846A2 (es) 2014-03-05
ES2445846R1 true ES2445846R1 (es) 2015-01-02

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201390009A Pending ES2445846R1 (es) 2010-07-21 2011-07-15 Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos

Country Status (30)

Country Link
US (1) US8617555B2 (enExample)
EP (2) EP2595658A2 (enExample)
JP (2) JP2013533268A (enExample)
KR (2) KR20130103486A (enExample)
CN (1) CN103118707A (enExample)
AR (1) AR082312A1 (enExample)
AU (1) AU2011281240B2 (enExample)
BR (1) BR112013001299A2 (enExample)
CA (1) CA2805961A1 (enExample)
CL (1) CL2013000200A1 (enExample)
CZ (1) CZ2013124A3 (enExample)
DE (1) DE112011102396T5 (enExample)
DK (1) DK201370089A (enExample)
EA (1) EA029847B1 (enExample)
EE (1) EE05761B1 (enExample)
ES (1) ES2445846R1 (enExample)
FI (1) FI20135152L (enExample)
FR (1) FR2962913A1 (enExample)
GB (2) GB2496799B (enExample)
IT (1) ITTO20110627A1 (enExample)
LT (1) LT5980B (enExample)
MX (1) MX2013000804A (enExample)
MY (1) MY160979A (enExample)
NO (1) NO20130265A1 (enExample)
NZ (1) NZ606964A (enExample)
PE (1) PE20130815A1 (enExample)
PH (1) PH12013500140A1 (enExample)
SE (1) SE1350212A1 (enExample)
SG (1) SG187578A1 (enExample)
WO (1) WO2012010966A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007149010A1 (en) * 2006-06-06 2007-12-27 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
CA2804966A1 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CN103154028A (zh) 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
WO2012007847A2 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
CN103119061A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 治疗注意力不足过动症的方法
ITTO20110630A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
PE20130387A1 (es) 2010-07-21 2013-03-30 Oleg Iliich Epshtein Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria
JP2013537532A (ja) * 2010-08-06 2013-10-03 イリイチ・エプシテイン オレグ 感染性疾患を治療及び予防する組み合わせ医薬組成物及び方法
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002555A1 (en) * 1996-07-12 1998-01-22 Salerno John C Applications for regulatory region of nos isoforms
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
CA2554045A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
WO2012007847A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
CN103154028A (zh) * 2010-07-15 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对神经退行性疾病相关的疾病或病症进行治疗的方法
CA2804966A1 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
ITTO20110630A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa
PE20130387A1 (es) * 2010-07-21 2013-03-30 Oleg Iliich Epshtein Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002555A1 (en) * 1996-07-12 1998-01-22 Salerno John C Applications for regulatory region of nos isoforms
US20100166762A1 (en) * 2000-06-20 2010-07-01 Oleg Iliich Epshtein Method of treating a pathological syndrome
EP2036574A1 (en) * 2006-06-06 2009-03-18 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jonas W. B. et al. A critical overview of homeopathy. Ann. Intern. Med. 2003, Vol. 138, páginas 393-399 (todo el documento) *
Shang A. et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. The Lancet. 27.08.2005, Vol. 366, páginas 726-732 (todo el documento) *
Vickers A. J. et al. Clinical Trials of Homeopathy and Placebo: Analysis of a Scientific Debate. The Journal of Alternative and Complementary Medicine. 2000, Vol. 6, Nº 1, páginas 49-56 (todo el documento) *

Also Published As

Publication number Publication date
BR112013001299A2 (pt) 2017-11-21
LT5980B (lt) 2013-12-27
PH12013500140A1 (en) 2013-03-11
FI20135152A7 (fi) 2013-02-21
GB201707872D0 (en) 2017-06-28
EA029847B1 (ru) 2018-05-31
WO2012010966A2 (en) 2012-01-26
NZ606964A (en) 2015-08-28
SG187578A1 (en) 2013-03-28
EE201300007A (et) 2013-08-15
EE05761B1 (et) 2016-03-15
JP2016222684A (ja) 2016-12-28
EP2595658A2 (en) 2013-05-29
CL2013000200A1 (es) 2015-01-23
GB2496799B (en) 2017-11-22
DE112011102396T5 (de) 2013-05-02
NO20130265A1 (no) 2013-04-18
EP3693018A1 (en) 2020-08-12
AR082312A1 (es) 2012-11-28
US20130064824A1 (en) 2013-03-14
AU2011281240B2 (en) 2016-07-07
LT2013018A (lt) 2013-10-25
KR20180127515A (ko) 2018-11-28
JP2013533268A (ja) 2013-08-22
FI20135152L (fi) 2013-02-21
MY160979A (en) 2017-03-31
KR20130103486A (ko) 2013-09-23
GB2552405A (en) 2018-01-24
GB2552405B (en) 2018-05-30
FR2962913A1 (fr) 2012-01-27
ES2445846A2 (es) 2014-03-05
US8617555B2 (en) 2013-12-31
CZ2013124A3 (cs) 2013-06-12
ITTO20110627A1 (it) 2012-01-22
DK201370089A (en) 2013-02-19
PE20130815A1 (es) 2013-07-18
GB201302924D0 (en) 2013-04-03
GB2496799A (en) 2013-05-22
CA2805961A1 (en) 2012-01-26
MX2013000804A (es) 2013-10-28
CN103118707A (zh) 2013-05-22
WO2012010966A3 (en) 2012-03-29
AU2011281240A1 (en) 2013-03-07
EA201300124A1 (ru) 2013-12-30
SE1350212A1 (sv) 2013-04-22

Similar Documents

Publication Publication Date Title
ECSP11011278A (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2013000200A1 (es) Una composicion de combinacion farmaceutica que comprende una forma activa potenciada de un anticuerpo al receptor de la insulina humana y una forma activa potenciada de un anticuerpo de la sintasa de no endotelial; metodo para tratar la diabetes y los trastornos metabolicos.
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
UY31228A1 (es) Ariloxazoles sustituidos y su uso
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
CR20110318A (es) Compuestos, composición farmacéutica y métodos para utilizarse en el tratamiento de trastornos metabólicos
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
UY31922A (es) Compuestos
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
CL2013001250A1 (es) Composicion intravenosa que contiene ibuprofeno y paracetamol combinados en dosis definidas; y uso en el tratamiento del dolor y/o inflamacion.
CL2012000797A1 (es) Compuestos derivados de pirazol, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que los comprende; y su uso para el tratamiento de una enfermedad o condicion tal como sindrome metabolico, diabetes, resistencia a la insulina, complicaciones diabeticas y trastornos del peso corporal.
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 20170828